|4/AAug 29, 5:53 PM ET

Gitman Paul 4/A

4/A · BIOSPECIFICS TECHNOLOGIES CORP · Filed Aug 29, 2018

Insider Transaction Report

Form 4/AAmended
Period: 2018-08-27
Gitman Paul
Director
Transactions
  • Sale

    Common Stock, $0.001 par value

    2018-08-27$50.11/sh10,000$501,14430,000 total
  • Sale

    Common Stock, $0.001 par value

    2018-08-29$49.79/sh4,000$199,17821,000 total
  • Sale

    Common Stock, $0.001 par value

    2018-08-28$48.88/sh5,000$244,41625,000 total
Footnotes (3)
  • [F1]The selling price of $50.1144 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $49.23 to $52.19. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F2]The selling price of $48.8831 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.68 to $49.41. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The selling price of $49.7946 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $49.35 to $50.00. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This amendment is being provided to correct the number of shares disposed of for the transactions reported on this line

Documents

1 file
  • 4
    form4a.xml

    AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES